Altium Capital Management LP Annovis Bio, Inc. Transaction History
Altium Capital Management LP
- $283 Million
- Q3 2024
A detailed history of Altium Capital Management LP transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Altium Capital Management LP holds 236,400 shares of ANVS stock, worth $713,928. This represents 0.67% of its overall portfolio holdings.
Number of Shares
236,400Holding current value
$713,928% of portfolio
0.67%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ANVS
# of Institutions
49Shares Held
1.25MCall Options Held
229KPut Options Held
934K-
Vanguard Group Inc Valley Forge, PA380KShares$1.15 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il103KShares$310,1290.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$304,1410.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.1KShares$299,3240.0% of portfolio
-
Merit Financial Group, LLC98.5KShares$297,5180.01% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $24.7M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...